Paxlovid is an oral antiviral medication used to treat COVID-19. If you’re at high risk for severe COVID-19 and take Paxlovid within five days of symptom onset, it can significantly reduce your risk of hospitalization.
Who Can Take Paxlovid?
Paxlovid is available for individuals aged 12 and older, based on their risk factors for severe COVID-19. The Food and Drug Administration (FDA) granted full approval to Paxlovid in May 2023 for adults with mild-to-moderate COVID-19 who are at high risk of severe illness, hospitalization, and death. Previously, an Emergency Use Authorization (EUA) was issued in December 2021 for individuals 12 and older (weighing at least 88 pounds). This EUA is still valid for adolescents and teens 12 and older who have mild-to-moderate disease and are at high risk of their infection becoming more severe.
Why is Paxlovid Important?
“It’s really our first efficacious oral antiviral pill for this virus,” explains Yale Medicine infectious diseases specialist Scott Roberts, MD. “It shows clear benefit, and it really can prevent hospitalization and death in people who are at high risk.”
How Effective is Paxlovid?
Clinical trials for Paxlovid, developed by Pfizer, showed an 89% reduction in the risk of hospitalization and death in unvaccinated individuals. This impressive result led the National Institutes of Health (NIH) to prioritize Paxlovid over other COVID-19 treatments. Subsequent studies have also demonstrated Paxlovid’s effectiveness in vaccinated individuals.
Key Takeaways
Paxlovid is a crucial tool in managing COVID-19, especially for those at high risk. Its ability to significantly reduce hospitalization and death makes it a vital antiviral treatment. Remember to consult with your healthcare provider to determine if Paxlovid is right for you.
Disclaimer: This information was accurate at the time of original publication and may be subject to change. Always refer to the CDC, WHO, and your local government for the most up-to-date information on COVID-19.
